Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334132 | 0.89 | MAOB (0.45) | MAOBMAOAMRGPRX4 | |
| SCHEMBL1336543 | 0.86 | MAOB (0.65) | MAOBMAOAMRGPRX4 | |
| SCHEMBL1335728 | 0.84 | MAOB (0.52) | MAOBMAOAMRGPRX4 | |
| SCHEMBL3363943 | 0.84 | MAOB (0.57) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL30152219 | 0.84 | MAOB (0.57) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL4338716 | 0.83 | MAOB (0.60) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL1336597 | 0.82 | MAOB (0.56) | MAOBMAOANR4A2MRGPRX4 | |
| SCHEMBL1335475 | 0.81 | MAPT (0.49) | — | |
| SCHEMBL1335673 | 0.81 | ATM (0.42) | MAOB | |
| SCHEMBL4342309 | 0.80 | MAOB (0.53) | MAOBMAOANR4A2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373626-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-24 | — | — | EP | disclosed |
| US-8354399-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-15 | — | — | US | disclosed |
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2373626-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010069966-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | MAOB 2699/4885MAOA 2960/4885NR4A2 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.